The study aims to randomize 320 (160 Caucasian, 160 African American) socially isolated
adults 75+ years old (50:50 split between those with normal cognition and mild cognitive
impairment (MCI)) recruited from the community to either the Video Chat Group or the Control
Group. The participants in the Video Chat Group will receive a computer and internet service
for the duration of the study, which they will use to video chat with study staff for 30
minutes/day 4x/week for 6 months (high dose), and then 2x/week for an additional 6 months
(maintenance dose). The efficacy examination of the maintenance dose is limited to an
exploratory aim. Both intervention and control groups will have a brief (about 10 minutes)
telephone check-in with study staff once per week. In-home testing will occur at Baseline and
6 months. A sub-sample of participants** will be assessed at 12 months (exploratory) after
additional 6 months of maintenance dose. All participants at OHSU will have their medication
compliance tracked using an electronic medication monitoring device and participants at both
OHSU and UM will have MRIs at Baseline and 6 months, if they are able to safely receive MRIs.
Participants at both sites will contribute saliva for genetic testing (optional consent), and
all video chat and neuropsychological assessment sessions will be recorded for speech and
language analysis (consent required for participation).